Drug Profile
Research programme: glioma diagnostics and therapeutics - Arch Biopartners
Alternative Names: MetaMxLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Arch Biopartners
- Developer Arch Biopartners; d3 Medicine
- Class Antineoplastics; Diagnostic agents; Imaging agents; Peptides
- Mechanism of Action Diagnostic imaging enhancers; Magnetic resonance imaging enhancers; Stem cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glioma
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Glioma in Canada
- 28 Apr 2021 No recent reports of development identified for preclinical development in Glioma(Diagnosis) in Canada
- 15 Apr 2019 Preclinical development for Glioma (Treatment and Diagnosis) is underway in Canada (Arch Biopartners website, April 2019)